Supernus Pharmaceuticals | SUPN - Ebit


Supernus Pharmaceuticals reported $-21.04M in EBIT for its fiscal quarter ending in June of 2026.





Ebit Change Date
Abbott USD 1.36B 775M Sep/2026
ANI Pharmaceuticals USD 39.84M 1.13M Jun/2026
Aurora Cannabis CAD 7.12M 42.91M Mar/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Canopy Growth CAD -145.65M 132.99M Mar/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Corcept Therapeutics USD 41.3M 90.9M Jun/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 13.09B 635M Sep/2026
Novo Nordisk DKK 33.76B 25.86B Jun/2026
Pacira USD 9.96M 5.33M Jun/2026
Perrigo USD 33.6M 50.8M Mar/2026
Pfizer USD -180M 5.16B Jun/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
United Therapeutics USD 375.6M 49.8M Jun/2026
Xeris Pharmaceuticals USD 9.12M 7.65M Mar/2026